What is Attention-Seeking Behavior?

Spravato success rate figures are easy to find and hard to compare. In the trial that supported its FDA approval, 69.3% of people who finished 4 weeks of Spravato with a new antidepressant had responded, and 52.5% were in remission. A study of routine care in Italy found 64.2% response and 40.6% remission at 3 months. The numbers answer slightly different questions, but they agree on the essentials: Spravato helps many people with treatment-resistant depression, response is more common than remission, and no single percentage tells the whole story.

Spravato also leaves a real share of people without enough relief.

Spravato is the brand name for esketamine, a nasal spray FDA-approved for treatment-resistant depression: depression that hasn't responded adequately to at least two antidepressants, each given at a proper dose for long enough.

What "Success" Means: Response vs. Remission

Nearly every Spravato statistic comes from one yardstick, the Montgomery-Åsberg Depression Rating Scale (MADRS). It's a 10-item interview a clinician scores from 0 to 60, where higher means more severe, and people entering Spravato's main approval trial averaged about 37. Two thresholds turn that score into a success rate:

• Response means the MADRS score has fallen by at least half from where it started.
• Remission means the score has dropped to 12 or lower, the cutoff the Spravato trials used.

The distance between the two is wide. Someone who starts at 38 and falls to 19 counts as a responder and may still have symptoms that get in the way of work, sleep, or relationships. Remission is the fuller recovery and the harder bar, so every remission figure below sits under its response figure.

Spravato's Success Rate in the Trial Behind Its Approval

The short-term trial that supported FDA approval was TRANSFORM-2, published in The American Journal of Psychiatry in 2019. Researchers at 39 outpatient centers enrolled adults with moderate to severe depression who hadn't responded to at least two antidepressants in their current episode. Everyone switched to a new oral antidepressant. One group also received Spravato, 56 or 84 mg twice a week, and the other a placebo spray. Of 227 people randomized, 197 finished the 4-week double-blind phase, and MADRS scores in the Spravato group fell 4 points more, on average.

The European Medicines Agency's review of the trial data translates that into response and remission:

Look first at the comparison group: more than half of the people who started a new antidepressant with a placebo spray also responded. The trial's finding is the gap. Among people who completed 4 weeks, adding Spravato meant about 17 more responders and 21 more remitters in every 100.

The counting method matters too, and it explains much of the inconsistency online. Figures near 69% count only people who finished. Figures near 63% for response, or 48% for remission, carry forward the last score of everyone who stopped early.

Real-World Success Rates

Trials select their patients carefully and follow them for weeks. Routine care is messier, which is what makes REAL-ESK useful. That 2022 study, published in the Journal of Affective Disorders, reviewed the medical records of 116 people with treatment-resistant depression treated with Spravato at several Italian mental health services, with assessments at 1 and 3 months.

By 3 months, 64.2% had responded and 40.6% were in remission, and both rates had climbed sharply between the first month and the third. The authors called that later response one of the study's novel findings. They also found no difference in effectiveness between people with other psychiatric conditions and people without them.

Lining those numbers up against TRANSFORM-2 doesn't work cleanly. REAL-ESK had no placebo or comparison group, everyone knew they were receiving Spravato, ratings weren't checked for consistency across centers, and 3 months is a different finish line from 4 weeks. It's encouraging evidence from everyday practice, not a controlled measure of effect.

Who Spravato Is Approved and Studied For

Spravato has two FDA-approved uses, built on separate trials, according to its prescribing information:

• Treatment-resistant depression in adults, on its own or with an oral antidepressant. The original 2019 approval required an oral antidepressant alongside it; standalone use was added in January 2025.
• Depression with acute suicidal thoughts or behavior, in adults with major depressive disorder, given alongside an oral antidepressant to treat the depressive symptoms.

The second use came from trials of a different group: adults with moderate to severe depression and active suicidal thoughts with intent, all of whom began with an inpatient psychiatric stay and standard care, and 63% of whom had attempted suicide before. Those results shouldn't be mixed with the treatment-resistant depression results.

The label is explicit about one boundary. Spravato hasn't been shown to prevent suicide or to reduce suicidal thoughts or behavior, and it doesn't replace hospitalization when that's needed, even if someone feels better after the first dose. It isn't approved for children. If suicidal thoughts are part of what you're living with right now, care for suicidal thoughts comes first, and 988 answers calls and texts at any hour.

How Fast Results Typically Appear

Spravato's reputation for speed comes from the first day. In TRANSFORM-2, most of the difference from placebo was already visible at 24 hours, the label reports; both groups kept improving through day 28, and the gap held steady rather than widening. The monotherapy trial behind the 2025 approval showed an effect at about 24 hours that lasted through day 28. In the suicidal-thoughts trials, the difference appeared as early as 4 hours.

Early movement isn't the same as response. In TRANSFORM-2, only 7.9% of people on Spravato had a response that began by day 2 and held through day 28, compared with 4.6% on placebo spray, a difference that wasn't statistically significant in the EMA review. The label calls for judging benefit at the end of the 4-week induction phase, after which sessions drop from twice a week to weekly.

And as REAL-ESK suggests, for some people even 4 weeks is early.

What Affects Individual Success

Research points to a handful of factors linked to outcomes, none of them a forecast for any one person:

• Time on treatment. Benefit is formally assessed after the 4-week induction phase, and in REAL-ESK, many responses and remissions arrived between the first and third month.
• Continuing after a good response. In a maintenance study described in the label, people in stable remission who kept taking Spravato went significantly longer before relapsing than people switched to a placebo spray, and the same held for people in stable response.
• Age. The evidence is weaker in older adults. In a separate short-term trial of adults 65 and older, response at day 28 was 27.0% with Spravato versus 13.3% with placebo spray, and the trial's main measure narrowly missed statistical significance, per the EMA review.
• Other psychiatric conditions. REAL-ESK found people with additional psychiatric diagnoses did as well as people without them.
• With or without an oral antidepressant. Spravato has shown benefit both ways, but no trial in the label compared the two head to head.

Limits and Risks

The same data show where Spravato falls short.

• Many people don't reach remission. Nearly half of the people who completed TRANSFORM-2 on Spravato weren't in remission at day 28, and in REAL-ESK, about six in 10 weren't in remission at 3 months.
• Not every trial was positive. Of the three short-term trials submitted for approval, only TRANSFORM-2 met its main goal. A fixed-dose trial in adults and the trial in older adults both fell short of statistical significance, according to the EMA review.
• It carries a boxed warning for sedation, dissociation, breathing problems (respiratory depression), and misuse or abuse, plus the risk of suicidal thoughts and behaviors that antidepressants carry for children and young adults. Sedation showed up in 48% to 61% of trial participants on Spravato, and dissociation, a sense of detachment that can warp time, space, or surroundings, in 61% to 84%.

Those risks shape how Spravato is given. It's only available through a restricted program called the Spravato REMS. You use the spray yourself under supervision in a certified healthcare setting, your blood pressure is checked before and after, and you're monitored for at least 2 hours before you're cleared to leave. Driving is off-limits until the next day, after a night of restful sleep. People with certain blood vessel problems, including an aneurysm, an abnormal connection between arteries and veins, or past bleeding in the brain, can't take it at all.

Talking to a Psychiatrist About Your Options

A Spravato success rate is a group statistic. It shows that Spravato helps a substantial share of people with treatment-resistant depression and that remission is harder to reach than response. It can't tell you what will happen for you. That depends on your diagnosis, what you've tried and for how long, your medical history, and the rest of your care.

We don't offer Spravato at Amae. Major depressive disorder is among the conditions our clinics specialize in, and when it hasn't eased with medication, our psychiatrists treat it within our integrated care model, which puts psychiatry, medication management, therapy, and primary care on one team. TMS therapy runs at three of our clinics: Los Angeles, Los Altos, and San Mateo. Our comparison of TMS, ketamine, and Spravato and our look at TMS success rates lay out how those options differ. To go over your history with someone who can see all of it, schedule an evaluation with an Amae psychiatrist. Anyone in immediate danger should call 911.

Frequently Asked Questions

What is Spravato's success rate in clinical trials?

In TRANSFORM-2, the short-term trial behind FDA approval, 69.3% of people who completed 4 weeks of Spravato plus a new antidepressant responded and 52.5% reached remission, versus 52.0% and 31.0% with a placebo spray plus a new antidepressant. Counting people who left early, remission was 48.2% versus 30.3%.

Does Spravato work better in real-world use than in trials?

The figures look similar, but they can't be compared directly. REAL-ESK, a study of 116 people treated in routine care in Italy, found 64.2% response and 40.6% remission at 3 months, with no placebo group and a longer follow-up than the 4-week trials.

How fast does Spravato start working?

Average scores often pull ahead of placebo within 24 hours, and in trials of people with suicidal thoughts, within 4 hours. A lasting response that early is uncommon, so benefit is judged after the 4-week induction phase, and some people improve later still.

Does Spravato work for everyone?

No. In TRANSFORM-2, nearly a third of people who completed treatment didn't respond, and nearly half didn't reach remission. Two other short-term trials, including one in adults 65 and older, didn't reach statistical significance on their main measure.

What happens if Spravato doesn't work for me?

A psychiatrist looks at the whole picture again: the diagnosis, whether treatment ran long enough, other medications, and other conditions. Next steps might include a different medication strategy, adding or changing therapy, or another treatment for treatment-resistant depression, such as TMS or ECT.

Is Spravato's success rate different for suicidal depression versus treatment-resistant depression?

Yes, and the two shouldn't be blended. The suicidal-thoughts trials measured average score changes 24 hours after the first dose in hospitalized adults receiving standard care. Spravato lowered depression scores more than placebo, but it didn't improve a rating of suicidality more than placebo, and it hasn't been shown to reduce suicidal thoughts.

Citations

1. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. The American Journal of Psychiatry. 2019;176(6):428-438. https://pubmed.ncbi.nlm.nih.gov/31109201/ (Tier 1)
2. European Medicines Agency. Spravato: EPAR public assessment report (EMA/614876/2019). 2019. https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf (Tier 2, regulatory review)
3. Martinotti G, Vita A, Fagiolini A, et al. Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). Journal of Affective Disorders. 2022;319:646-654. https://pubmed.ncbi.nlm.nih.gov/36167246/ (Tier 1)
4. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised April 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf (Tier 2)
5. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

Days go by without a real conversation. Invitations stopped coming, or you stopped saying yes. At first it felt like rest. Now it feels like a wall. If you've been wondering what isolation is doing to you, or to someone you love, the research has a fairly clear answer: the negative effects of social isolation reach mood, the heart, sleep, and memory, and they build over time.

The good news is that connection works in both directions. The same research that shows the harm also suggests that rebuilding contact, even in small steps, matters.

What is social isolation?

The CDC defines social isolation as not having relationships, contact with, or support from others. It's something you can count: how often you talk to people, whether anyone would help in a crisis, whether you're part of any group.

Loneliness is different. It's the feeling of being alone or disconnected, the gap between the connection you have and the connection you want. You can be isolated without feeling lonely, and you can feel lonely in a room full of friends. The two often feed each other, and both carry health risks.

They're also common. According to the CDC, about 1 in 3 U.S. adults report feeling lonely, and about 1 in 4 report not having social and emotional support.

Who is most at risk?

The CDC lists several factors that raise the risk of isolation and loneliness, including:

• A chronic physical illness, disability, or a psychiatric or depressive condition
• Divorce, unemployment, or the loss of a loved one
• Living in a rural area, limited transportation, or language barriers
• Being a victim of violence or abuse
• Older age, living alone, low income, and being a young adult

Mental health conditions sit on both sides of the equation. Depression, anxiety, and psychosis can make people pull away, and isolation can make those conditions worse.

What does isolation do to a person mentally?

Depression

In a 2017 population-based study in PLOS ONE of 1,919 adults in Singapore, weak connections with relatives and friends, and loneliness, were both associated with more depressive symptoms, even after accounting for age, gender, employment, and other factors. Loneliness had the strongest association. The study was cross-sectional, so it shows a link rather than proving which came first, but the pattern matches what the CDC reports: isolation and loneliness raise the risk of depression and anxiety.

Suicidality and self-harm

The CDC also lists suicidality and self-harm among the health risks of isolation and loneliness. If you or someone you know is having thoughts of suicide, call or text 988, the Suicide & Crisis Lifeline. Reaching out is a form of connection too.

Withdrawal as an early warning sign

Sometimes isolation is a symptom rather than a cause. The NIMH lists withdrawing socially and spending much more time alone among the warning signs that can appear before a first episode of psychosis. Pulling away from people can also be a sign of depression, something we describe in what severe depression feels like. A sudden or growing withdrawal, especially in a teen or young adult, deserves attention. With psychosis, early care makes a difference. Read more about how we treat psychosis.

Effects of social isolation on the body

Heart disease and stroke

A 2022 scientific statement from the American Heart Association reviewed the research on isolation and cardiovascular health. It cited a meta-analysis in which social isolation or loneliness was linked to a 29% higher risk of coronary heart disease and a 32% higher risk of stroke. The authors also noted that the effect estimates are small and that unmeasured factors may play a role.

Stress hormones and inflammation

Isolation shows up in the body's stress systems. In a 2021 study in Psychoneuroendocrinology of 314 adults from the Midlife in the United States (MIDUS) study, living alone was associated with a flatter daily cortisol rhythm and higher C-reactive protein, a marker of inflammation. Loneliness was separately associated with higher levels of another inflammatory marker, IL-6.

A larger 2025 study in Nature Human Behaviour of 42,062 UK Biobank participants identified blood proteins linked to isolation and loneliness. Many were involved in inflammation and immune responses, and more than half were linked to later heart disease, type 2 diabetes, stroke, and death.

Earlier death

A 2015 meta-analysis in Perspectives on Psychological Science found that social isolation was associated with a 29% higher likelihood of death, loneliness with 26%, and living alone with 32%, after controlling for other factors. The authors concluded the risk is comparable to other well-established risk factors for mortality.

Effects on memory and the brain

In the English Longitudinal Study of Ageing, researchers followed 11,233 adults aged 50 and older over six assessments, two years apart. Isolation was associated with faster memory decline, particularly in men who were highly isolated at the start and in women whose isolation grew over time. The analysis suggested isolation contributed to memory decline, rather than poor memory causing isolation.

Dementia risk follows a similar pattern. In a nine-year U.S. study of 5,022 older adults published in the Journal of the American Geriatrics Society, being socially isolated was associated with a 28% higher risk of developing dementia, with no significant difference by race or ethnicity.

Signs that isolation is taking a toll

• Going days without a meaningful conversation
• Declining invitations or avoiding calls and messages
• Losing interest in activities you used to enjoy
• Sleep changes, low energy, or changes in appetite
• Persistent sadness, irritability, or feeling numb
• Neglecting self-care or your home
• Feeling like no one would notice if you disappeared

The last one is important. Feeling invisible or like a burden is a warning sign, and it's a reason to reach out today, or to call or text 988.

Can the effects of social isolation be reversed?

Much of the research is observational, so it shows risk rather than a guaranteed path back. But the ageing study found the strongest memory effects in people whose isolation was high or growing, which suggests the pattern over time matters. Reconnecting helps at any point, and the earlier the better.

Practical steps that help people rebuild contact include:

• Start small. One text, one short call, one coffee. Consistency matters more than size.
• Schedule it. Put regular check-ins with a friend or family member on the calendar.
• Join something structured. A class, volunteer role, faith community, or interest group gives you a reason to show up.
• Mix in-person and digital. Video calls help, but protect some in-person time too.
• Lower the bar. You don't need a deep conversation. Being around people counts.

If depression, anxiety, or another condition is what's keeping you isolated, treating it often makes reconnection possible in a way willpower alone doesn't.

When to get professional help

Talk to a mental health professional if isolation comes with persistent low mood, intense anxiety, loss of interest, neglect of basic self-care, or hopelessness that lasts for weeks. Get help sooner if someone is withdrawing alongside confused thinking, unusual beliefs, or hearing or seeing things others don't.

At Amae Health, our clinics specialize in conditions including Major Depressive Disorder, bipolar disorder, schizophrenia, and first-episode psychosis, where withdrawal is often part of the picture. Our care teams include psychiatrists, therapists, primary care physicians, care coordinators, and peer mentors who help with counseling and life skills. Group therapy is part of care too. For more on levels of care, see inpatient vs. outpatient mental health treatment. If reaching out feels hard, our guide on how to ask for help when depressed may help.

Frequently asked questions

What is the difference between social isolation and loneliness?

Social isolation is an objective lack of relationships, contact, or support. Loneliness is the subjective feeling of being alone or disconnected. You can have one without the other, and both are linked to health risks.

What does social isolation do to a person?

Research links isolation to more depressive symptoms, higher risk of heart disease and stroke, changes in stress hormones and inflammation, faster memory decline, higher dementia risk, and earlier death. Most of these findings are associations, and the risks build over time.

Why is isolation bad for your mental health?

Isolation removes support, routine, and the everyday contact that helps regulate mood. The CDC lists depression, anxiety, and suicidality among its health risks. Isolation can also be a symptom of depression or psychosis, which makes it a signal to notice.

How can I tell if someone is isolating because of a mental health condition?

Watch for withdrawal that's new or growing, combined with changes like low mood, poor self-care, confused thinking, or unusual beliefs. Ask directly and kindly how they're doing, and encourage an evaluation if the changes persist.

Key takeaways

• Social isolation is a lack of contact and support. Loneliness is the feeling of disconnection. Both carry health risks.
• Research links isolation to depression, heart disease and stroke, inflammation, memory decline, dementia, and earlier death.
• Withdrawal can also be an early sign of depression or psychosis.
• Small, regular steps toward connection help, and treating an underlying condition can make reconnecting possible.

If isolation is part of a bigger pattern of depression, mood swings, or changes in thinking, for you or someone you love, request an intake appointment. Our team will explain how an evaluation works and what the first visit involves.

Maybe a genetic report flagged it. Maybe a friend, a forum, or a supplement ad told you it could explain your fatigue, your depression, or why medication never quite worked. Now you're wondering what an MTHFR gene mutation actually means for you.

MTHFR variants are extremely common. Most people who carry them have no health effects at all, and research linking them to mental health conditions shows a real but small association, not a cause. Medical experts don't recommend routine testing for them.

What the MTHFR gene does

The MTHFR gene carries instructions for an enzyme called methylenetetrahydrofolate reductase. That enzyme converts folate, a B vitamin, into the active form your body uses to turn the amino acid homocysteine into methionine. According to MedlinePlus Genetics, the active form, 5-methyltetrahydrofolate, is the main form of folate found in blood.

When the enzyme works less efficiently, homocysteine can build up. That's the mechanism behind most of the interest in MTHFR, including the mental health questions.

C677T, A1298C, heterozygous, and homozygous

Most people searching "MTHFR gene mutation" are really asking about two common variants:

• C677T. The most common and best studied. At position 677 in the gene, the DNA base C is replaced by T. The resulting enzyme is less stable and less active, especially in people with two copies.
• A1298C. The second common variant. The CDC notes there isn't enough evidence that A1298C on its own significantly affects how the body processes folate.

You inherit one copy of the gene from each parent, which is where the lab terms come from:

• Heterozygous means one copy carries the variant (for C677T, written CT).
• Homozygous means both copies carry it (TT).
• Compound heterozygous means one copy of C677T and one copy of A1298C.

These variants are so common they're closer to normal human variation than to a disease. The CDC reports that more people in the U.S. have one or two copies of C677T than don't. Having both copies is less common: MedlinePlus estimates about 25% of Hispanic people and 10% to 15% of North American white people carry two copies of C677T.

MTHFR symptoms: what the variant does and doesn't cause

Most people with common MTHFR variants have no symptoms. Cleveland Clinic puts it plainly: MTHFR gene variants most often don't affect your health or cause symptoms. When they do matter, it's usually through higher homocysteine or lower folate, and mostly in people with two copies of C677T. Even then, how much folate you get from food matters more than your genotype.

That's different from what you'll read on many wellness sites, which attribute everything from fatigue to brain fog to MTHFR. There's no reliable evidence for a list of "MTHFR symptoms" in people with the common variants. If you have symptoms, they deserve an evaluation, not an assumption that a gene variant explains them.

There is one important exception. Rare, severe mutations in the MTHFR gene cause homocystinuria, a serious inherited condition whose symptoms usually appear early in life. Most U.S. newborns are screened for it shortly after birth. That's a different situation from the common C677T and A1298C variants.

MTHFR and mental health: what research shows

Because MTHFR sits in the folate and methylation pathway, researchers have looked hard for links to psychiatric conditions. The findings are consistent in one way: the effect is modest.

• Depression. A 2013 meta-analysis of 26 studies, with 4,992 people with depression and 17,082 controls, found that two copies of C677T were associated with higher odds of depression (odds ratio 1.42). The link was stronger in Asian populations, marginal in white populations, and absent in older adults.
• Schizophrenia, bipolar disorder, and depression combined. A 2011 meta-analysis of case-control studies with 29,502 participants found TT carriers had modestly higher odds of these conditions as a group (odds ratio 1.26). The authors read this as evidence of a shared genetic vulnerability across the three conditions.

An odds ratio of 1.26 to 1.42 is a small increase in relative risk for a very common genotype. Most people with two copies of C677T never develop depression, bipolar disorder, or schizophrenia, and most people with those conditions don't have two copies. Mental health conditions come from many genes and life experiences acting together. MTHFR is, at most, one small piece.

Folate, folic acid, and methylfolate

A common online claim is that people with MTHFR variants can't use folic acid and need "methylated" supplements instead. The CDC says that isn't true: people with an MTHFR variant can process all types of folate, including folic acid. People with the TT genotype have blood folate levels only about 16% lower on average than people with CC at the same intake, and folic acid intake matters more than genotype in determining blood folate.

L-methylfolate, the active form, has been studied as an add-on to antidepressants. In two randomized trials published in the American Journal of Psychiatry in 2012, adults with depression that hadn't responded fully to an SSRI received L-methylfolate or placebo alongside their medication. The first trial, with 148 patients starting at 7.5 mg a day, found no difference. The second, with 75 patients at 15 mg a day, found a significant benefit over placebo. Both enrolled people based on their depression, not on a genetic test. Whether any add-on makes sense for a specific person is a clinical decision that depends on their full history.

For more on how folate and other nutrients relate to mood, see our article on nutrient deficiencies and anxiety.

Should you get tested for MTHFR?

For most people, no. MedlinePlus states that medical experts don't recommend testing for common MTHFR gene changes in most cases. A provider may order it in specific situations, such as high homocysteine on a blood test combined with a family history.

The American College of Medical Genetics and Genomics went further in a 2013 practice guideline: MTHFR polymorphism testing has minimal clinical utility and shouldn't be part of a routine evaluation for blood clotting disorders. Recent meta-analyses had disproven the links that originally motivated the testing.

If you already have a result, it's still useful context to share with your care team. It just isn't a diagnosis, and it isn't a treatment plan.

When depression or mood symptoms don't improve

People often look up MTHFR because something isn't working: depression that keeps coming back, medication that only half helps, or mood swings no one has explained. Those problems are real, even if MTHFR is unlikely to be the answer. They usually call for a fuller psychiatric evaluation: a closer look at the diagnosis, past medication trials, co-occurring conditions, sleep, substance use, and physical health.

That's the kind of care we provide at Amae Health. Our clinics specialize in conditions including Major Depressive Disorder, bipolar disorder, and schizophrenia. Our care teams bring psychiatrists, therapists, primary care physicians, and dietitians under one roof, so lab results, nutrition, and medication history are reviewed together, by people who share one treatment plan. See how our integrated outpatient clinics work.

Frequently asked questions

How common is the MTHFR gene mutation?

Very common. According to the CDC, more people in the U.S. have one or two copies of the C677T variant than don't. Two copies are less common, estimated at about 25% of Hispanic people and 10% to 15% of North American white people.

What are the symptoms of being MTHFR C677T heterozygous?

Usually none. According to MedlinePlus, raised homocysteine is seen mainly in people with two copies of C677T. If you have symptoms, they need an evaluation of their own rather than being attributed to one copy of a common variant.

Does MTHFR cause depression?

No single gene causes depression. Two copies of C677T are associated with modestly higher odds of depression in meta-analyses, with an odds ratio around 1.4, but most people who carry them never develop depression.

Do people with MTHFR need methylfolate instead of folic acid?

According to the CDC, no. People with MTHFR variants can process folic acid, and folic acid intake matters more than genotype for blood folate levels. L-methylfolate has been studied as an add-on treatment for depression, regardless of MTHFR status, and decisions about it belong with a clinician.

Is MTHFR testing worth it?

For most people, it isn't recommended. Medical genetics experts say the common variants have minimal clinical utility. A provider may order testing in specific cases, such as unexplained high homocysteine with a family history.

Key takeaways

• An MTHFR gene mutation usually means one or two copies of the common C677T or A1298C variants, which most people carry without health effects.
• Two copies of C677T can raise homocysteine and are linked to modestly higher odds of depression, bipolar disorder, and schizophrenia, but the effect is small.
• People with MTHFR variants can process folic acid, and routine MTHFR testing isn't recommended.
• If depression or mood symptoms aren't improving, a full psychiatric evaluation is more useful than a gene result.

If you or someone you love is living with depression, bipolar disorder, or schizophrenia that hasn't responded to treatment, request an intake appointment. Our team will walk you through how an evaluation works and what to bring, including any lab or genetic results you already have.